ProQR Therapeutics (PRQR)
(Real Time Quote from BATS)
$2.04 USD
-0.08 (-3.55%)
Updated Aug 6, 2025 11:34 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRQR 2.04 -0.08(-3.55%)
Will PRQR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRQR
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
Best Momentum Stocks to Buy for October 2nd
Other News for PRQR
ProQR Announces Upcoming Presentation at RNA Editing Summit | PRQR Stock News
ProQR Therapeutics (PRQR) Target Price Boosted by Evercore ISI | PRQR Stock News
ProQR Therapeutics price target raised by $1 at Evercore ISI, here's why
PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stock News
ProQR Therapeutics (PRQR) Analyst Rating Maintained by JMP Securities | PRQR Stock News